Background: Liver function tests may help to predict outcomes after liver surgery. The aim of this study was to evaluate the clinical impact on postoperative outcome and patient management of perioperative liver function testing using the LiMAx ® test. 
Introduction
Liver resection is the treatment of choice for most hepatic malignancies and has become a safe and effective surgical procedure 1 . Major resection and underlying hepatic injury, however, increase the risk of postoperative liver failure with consecutive morbidity and mortality. The lack of suitable diagnostic tests to predict the individual risk of postoperative liver failure led to the development of the LiMAx ® test (Humedics, Berlin, Germany), a 
Methods

Study design
This study was a phase III, multicentre, two-arm, parallelgroup, open-label RCT. Patients were recruited from six German academic centres specialized in complex liver surgery. The trial followed the ethical guidelines of the 1975 Declaration of Helsinki and the CONSORT 2010 guidelines 20 . The protocol was approved by the responsible ethics committee and approved by the German Federal Institute for Drugs and Medical Devices. The trial was registered as NCT01785082 (ClinicalTrials.gov).
Participants
Patients aged 18 years or more with benign or malignant intrahepatic tumours scheduled for open liver resection of at least one segment were eligible; they were included after written informed consent had been obtained. Contrast-enhanced three-phase thin-layer CT or high-quality MRI of the liver within the past 6 weeks was required for resection planning. Exclusion criteria were expected vascular or biliary anastomosis, history of previous liver resection, known liver cirrhosis or severe fibrosis, and severe co-morbidities requiring postoperative telemetry. In the study protocol, criteria were defined that allowed for replacement of participants if the planned procedure was not performed owing to, for example, advanced tumour stage or tumour extension to other solid organs.
Randomization
Before randomization, surgeons determined each patient's postoperative care, including the indication of postoperative transfer to a telemetry unit (providing continuous cardiac, haemodynamic and respiratory monitoring, typically on the intermediate care unit (IMCU) or ICU). The assignment was documented with date and time, and signed by the responsible surgeon. Thereafter, patients were randomized either to the intervention arm (LiMAx ® group) or to the standard-care arm (control group) in a ratio of 1 : 1 at each centre. The randomization was stratified for each centre and each preoperative assignment (postoperative care on general ward versus telemetry on the IMCU/ICU) using sealed, sequentially numbered, randomization envelopes provided by IFS (Institute for Applied Research and Clinical Studies), Göttingen, Germany. Patient enrolment and randomization were performed by trained study investigators at the study centres.
Intervention
Two LiMAx ® test assessments were performed in patients in the intervention group. The first test was done the day before surgery for individual surgical planning. The resection strategy and intraoperative procedures were adopted before surgery according to the LiMAx ® decision tree algorithm for hepatectomy 3 Sterile [ 13 C]methacetin solution (Humbedics, Berlin, Germany) was administered intravenously at a dose of 2 mg/kg bodyweight. Breath analysis was performed using a novel CE-certified medical device (FLIP ® ; Humedics). The entire exhaled breath is collected by a specific face mask (Humedics) and transferred through the FLIP ® device for quantitative real-time determination of 12 CO 2 and 13 CO 2 concentration using a quantum cascade laser 25, 26 . The LiMAx ® test result (given in micrograms of substrate metabolism per h, normalized to bodyweight) is calculated by the device and provided within 20 min to a maximum of 60 min after substrate administration. The normal value was defined as greater than 315 μg per kg per h in a previous study of healthy controls 27 .
Study endpoints
The primary endpoint was the proportion of patients who could be safely transferred from the recovery room to a general ward. The accuracy of the primary postoperative allocation to a general ward was evaluated by the following criteria: no transfer to the IMCU/ICU after transfer to a general ward and regular discharge on postoperative day 30 at the latest (true positive). Patients primarily allocated to the IMCU/ICU (LiMAx ® value of 150 μg per kg per h or less in the intervention arm and preoperative assignment in the control arm) were reviewed retrospectively by a group of three LiMAx ® -blinded, study-independent ICU experts. Only when these assessors unanimously confirmed the medical indication for each postoperative IMCU/ICU transfer based on their clinical experience was the transfer rated retrospectively as appropriate (true negative). The decision of the assessors was recorded for each reviewed patient. Secondary study endpoints included the proportion of patients who developed posthepatectomy liver failure (PHLF), graded according to Rahbari et al. 28 , and postoperative complications, graded according to Clavien-Dindo 29 . Complications of grade IIIa and above were considered severe. Additional endpoints were length of hospital stay (LOS) and length of IMCU/ICU (LOI) stay. (SAS Institute, Cary, North Carolina, USA). P < 0⋅050 was considered statistically significant.
Sample-size calculation
Results
A total of 149 patients were assessed for eligibility between January 2013 and September 2015 (Fig. 1) . One patient was excluded due to a screening failure (previous liver resection) before surgery. Some 141 patients (95⋅3 per cent) were planned for postoperative transfer to the IMCU/ICU, and the remaining seven patients (4⋅7 per cent) were planned for direct postoperative transfer to a general ward. These assignments reflected the conservative standard-care patient management after open liver resection in all participating centres. Of the seven patients allocated for direct postoperative transfer to the general ward, four were randomized to the LiMAx ® group and three to the control group. Twenty-five randomized patients (13 in the LiMAx ® group and 12 in the control group) were replaced in accordance with the study protocol. Criteria were: surgery not performed/postponed (7 patients), intraoperative change of procedure due to advanced tumour disease (16) , and extension of operative procedure to thoracic or other abdominal organs (2) . Five patients in the LiMAx ® group Values in parentheses are percentages unless indicated otherwise.
were excluded because no postoperative LiMAx ® test had been performed. Thus, a total of 118 patients, 58 in the LiMAx ® group and 60 in the control group, were eligible for analysis.
Demographics and surgical procedures
Baseline characteristics are shown in Table 1 . The majority of patients had surgery for colorectal liver metastases. The most frequent co-morbidity was hepatic steatosis. Types of operation were comparable in the two groups ( In the control group, three patients had been considered as potentially suitable for transfer to a general ward. Two of these patients were assessed after surgery by the responsible physician as not suitable for transfer to a general ward. Thus, only one patient in the control group originally planned for transfer to a general ward was finally transferred to a general ward. This patient stayed on the general ward until regular discharge within 30 days.
In the group with a postoperative LiMAx ® value of 150 μg per kg per h or less, the three external assessors did not confirm the need for postoperative telemetry in four patients. In the control group, 57 of 60 patients had a preoperative assignment to the IMCU/ICU, but this transfer decision was not deemed necessary by the external assessors for 24 of them (42 per cent).
Length of stay
Time-to-event curves for LOI were evaluated for 58 patients in the LiMAx ® group and 57 in the control group (Fig. 2) . Three of the control group patients were censored (patient still in IMCU/ICU at postoperative day 30). Mean LOI stay was 0⋅8 days for the LiMAx ® group and 3⋅0 days for the control group (P < 0⋅001), representing a 73⋅3 per cent reduction in total IMCU/ICU days. Values in parentheses are percentages. *Cochran-Mantel-Haenszel test stratified for centre.
Patients in the LiMAx ® group had a shorter postoperative hospital stay than those in the control group (mean LOS 10⋅6 versus 13⋅3 days respectively; P = 0⋅012).
Overall complication rate and mortality
The rate of severe complications was significantly lower in the LiMAx ® group than in the control group (14 (95 per cent c.i. 6 to 25) versus 28 (17 to 41) per cent respectively; P = 0⋅022) ( Table 3) . No statistically significant differences were observed for grade I or II complications. One patient in each study group died. The patient who died in the control group developed postoperative pulmonary embolism leading to terminal right heart failure on postoperative day 18. The patient in the LiMAx ® group developed myocardial infarction during surgery leading to intraoperative resuscitation and interruption of liver resection; the patient subsequently developed irreversible right heart failure. One patient in each group developed posthepatectomy liver failure.
Discussion
The use of liver function tests before and immediately after surgery resulted in significantly more patients being sent to the surgical ward after liver resection. Subsequently, the severe complication rate was lower, and LOI stay and LOS were significantly shorter in these patients. The decision also to use the LiMAx ® test after surgery in the intervention arm was made for several reasons, including the frequency of both change in operation plans and additional intraoperative hepatic injury owing to intraoperative bleeding, inflow occlusion or less perfused resection margins. The primary endpoint of primary transfer to a general ward was chosen as this is a simple and comprehensive marker involving all preoperative, intraoperative and postoperative parameters of patient management, including residual liver function. 35 . In contrast, patients on a general ward routinely receive oral feeding and early mobilization as soon as possible, which is known to be a crucial factor in preventing postoperative complications 36 . Although such data were not collected explicitly, the present results suggest that patients did receive earlier oral feeding and/or mobilization after being sent directly to a general ward, according to common clinical practice in most liver centres. The study has several limitations. Patients with complex liver resections including biliary or vascular reconstructions, and patients with previous resections or pre-existing fibrosis or cirrhosis, were excluded from participation, even though such patients might derive even greater benefit from perioperative liver function assessment by the LiMAx ® test. The risk of severe postoperative complications, particularly PHLF, is expected to be much higher for patients with complex liver resections than in the investigated population 2, 6, 37 . The number of IMCU/ICU admissions in the control group was very high. In view of the present results, the conservative transfer policy might be changed in future. The LiMAx ® test helps to transfer the patient to the right setting after liver surgery. Other factors, such as perioperative bleeding, spontaneous breathing, haemodynamic stability and adequate analgesia, are important, however, to guide postoperative transfer decision.
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